Pubblicazioni

Autori:

Fabris M; Quartuccio L; Lombardi S; Saracco M; Atzeni F; Carletto A; Cimmino M; Fabro C; Pontarini E; Pellerito R; Bambara LM; Sarzi-Puttini P; Cutolo M; Manfredi M; Benucci M; Morassi P; Fischetti F; Padovan M; Govoni M; Curcio F; Tonutti E; De Vita S

Titolo:

The CC homozygosis of the -174G>C IL-6 polymorphism predicts a lower efficacy of rituximab therapy in rheumatoid arthritis

Anno:

2010

Tipologia prodotto:

Articolo in Rivista

Tipologia ANVUR:

Articolo su rivista

Nazioni degli autori:

ITALIA

Lingua:

Inglese

Formato:

Elettronico

Referee:

Sì

Nome rivista:

AUTOIMMUNITY REVIEWS

ISSN Rivista:

1568-9972

Intervallo pagine:

1-24

Codice PMID:

20974296

Parole chiave:

IL-6, pharmacogenetics, rituximab, rheumatoid arthritis

Breve descrizione dei contenuti:

Identification of genetic biomarkers of response to biologics in rheumatoid arthritis (RA) is a relevant issue. Being IL-6 a key cytokine for B cell survival, the interleukin-6 (IL-6) -174G>C and the IL-6 receptor (IL-6R) D358A gene polymorphisms were investigated in 158 RA patients treated with rituximab (RTX). One hundred and twenty-eight (81.0%) were RF-positive and 126 (79.7%) were anti-CCP positive. Response to therapy was evaluated at the end of the sixth month after the first RTX infusion, by using both the EULAR and the ACR criteria. The possible relationship with IL-6 serum levels was also studied. By univariate analysis, lack of response by the EULAR criteria was more prevalent in RA patients with the IL-6 -174 CC genotypes (39.1 %), than in the GC/GG patients (18.5 %) (OR 2.83; 95% CI = 1.10-7.27; p=0.031). A good response was noticed in only one patient (4.3%) with the IL-6 -174 CC genotype, while it was present in 24.4% of GG/GC cases (p=0.06). By stepwise multivariate analysis (including RA duration, baseline DAS28, baseline HAQ, RF status, anti-CCP status and IL-6 genotype as covariates), the IL-6 -174CC genotype was selected as an independent predictor of no response to RTX by both EULAR and ACRe50 criteria, while the IL-6R polymorphism resulted not associated. No definite association between gene polymorphisms and IL-6 serum levels was noticed. Present results suggest a possible role for IL-6 genotyping to better plan treatment with RTX in RA, and larger studies are worthwhile.

Id prodotto:

57958

Handle IRIS:

11562/345943

depositato il:

28 ottobre 2010

ultima modifica:

2 novembre 2016

Citazione bibliografica:

Fabris M; Quartuccio L; Lombardi S; Saracco M; Atzeni F; Carletto A; Cimmino M; Fabro C; Pontarini E; Pellerito R; Bambara LM; Sarzi-Puttini P; Cutolo M; Manfredi M; Benucci M; Morassi P; Fischetti F; Padovan M; Govoni M; Curcio F; Tonutti E; De Vita S, The CC homozygosis of the -174G>C IL-6 polymorphism predicts a lower efficacy of rituximab therapy in rheumatoid arthritis «AUTOIMMUNITY REVIEWS» , 2010 , pp. 1-24

Consulta la scheda completa presente nel repository istituzionale della Ricerca di Ateneo